Your browser doesn't support javascript.
loading
Outcome of Infants Born to Women with Chronic Hepatitis B: A Local Risk-Based Strategy in a Low Prevalence Country.
Copiz, Giannina Izquierdo; Ibañez, Carolina; Piñera, Cecilia; Cordova, Luis; Payá, Ernesto; Leal, Paula; Villena, Rodolfo.
Afiliación
  • Copiz GI; Department of Pediatrics, Faculty of Medicine, Universidad de Chile, Santiago, Chile. gizquierdo@uchile.cl.
  • Ibañez C; Maternity Ward and Neonatal Intensive Care Unit, Complejo Asistencial Barros Luco, Santiago, Chile. gizquierdo@uchile.cl.
  • Piñera C; Infectious Diseases Unit, Hospital de niños Dr. Exequiel González Cortés, Santiago, Chile. gizquierdo@uchile.cl.
  • Cordova L; Department of Pediatrics, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Payá E; Department of Pediatrics, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile.
  • Leal P; Department of Pediatrics, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Villena R; Infectious Diseases Unit, Hospital de niños Dr. Exequiel González Cortés, Santiago, Chile.
Matern Child Health J ; 28(4): 767-774, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38358537
ABSTRACT

BACKGROUND:

Chronic hepatitis-B virus (HBV) infection due to mother-to-child transmission (MTCT) during the perinatal period is an important global health concern. Chile is a low-prevalence country with an increasing migratory inflow from Latin- American countries, with intermediate to high endemic rates of HBV infection, and until 2021, there is no universal maternal screening. This study aimed to evaluate infant outcomes using a risk-based strategy of maternal screening to prevent MTCT of hepatitis B virus (HBV) in a low-prevalence country.

METHODS:

This prospective study included infants born to HBsAg-positive women detected using a local risk-based strategy. The exposed infants received immunoprophylaxis (IP) and follow-up to evaluate their clinical outcomes and immune responses through post-serological vaccine testing (PSVT) after completing the three- dose schedule of the HBV vaccine.

RESULTS:

A total of 99 HBsAg-positive mothers were detected. Seventy-six (82%) infants completed the follow-up and had PSVT between 9 and 12 months of age. 55.2% female, the median gestational age was 39 weeks (25-41) and the median birth weight was 3,130g (816-4,400 g). All patients received IP with recombinant HBV vaccine plus hepatitis-B virus immunoglobulin (HBIG) and three doses of the HBV vaccine. There were no cases of HBV infection, and 96% (72) responded to immunization with HBsAg antibodies (anti-HBsAg) >10 UI/ml, with a median level of 799 IU/ml.

CONCLUSIONS:

A high-risk strategy can be implemented in countries with non-universal screening for VHB. Timely IP plus high-uptake VHB vaccination in infants born to HBsAg-positive mothers was associated with a high immunogenic response and absence of MTCT.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Complicaciones Infecciosas del Embarazo / Hepatitis B Crónica / Hepatitis B Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Female / Humans / Infant / Male / Pregnancy Idioma: En Revista: Matern Child Health J Asunto de la revista: PERINATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Chile Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Complicaciones Infecciosas del Embarazo / Hepatitis B Crónica / Hepatitis B Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Female / Humans / Infant / Male / Pregnancy Idioma: En Revista: Matern Child Health J Asunto de la revista: PERINATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Chile Pais de publicación: Estados Unidos